Golden Biotechnology Corp. (GBC) received approval for a new patent of its developing new drug Antroquinonol by the USPTO (United States Patent and Trademark Office) for “Methods and Compositions for Treating Neurodegenerative Diseases.” The methods are for alleviating, abating and ameliorating the symptoms as well as for reducing the risk of neurodegenerative disease caused by neuronal damage.
The approved claims include the treating of neuronal degenerative diseases caused by neuronal damage, as well as the inhibition of the b-Amyloid induced neuronal damage in the body. The claimed diseases include Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, stroke syndromes, Down syndrome and amyotrophic lateral sclerosis.
GBC had received a patent for the treatment of neurodegenerative diseases approved by the Taiwan IPO in 2016 (Patent No. I559917). GBC has applied the related patents in nearly 50 countries around the world.
Accumulations of a large amount of b-Amyloid in the nervous system are observed in many neurological diseases and may lead to the degeneration or dysfunction of the brain or other organs, as seen in Alzheimer’s disease, which is the most common cause of dementia.
Alzheimer’s disease (AD) is a serious public-health issue related to the aging problems of the global population and changing of lifestyles. In the United States, for example, there are currently nearly 5.4 million AD patients, and the expected number of patients could reach 16 million by 2050. Nearly $37 billion was spent by the United States on Alzheimer’s care and related brain-degenerative diseases in 2011, while the cost of related derivative healthcare was as high as $203 billion in 2013 and is expected to reach $1.2 trillion in 2050.
GBC won an award from the Advance Queensland – Johnson & Johnson Innovation QuickFire Challenge in the pharmaceutical category in Australia in 2016 for their work in developing a potential treatment for Alzheimer’s disease. GBC and the Queensland government had jointly conducted a cooperation project for Alzheimer’s disease in 2017.
GBC is collaborating with the Institute of Health and Biomedical Innovation (IHBI) at QUT to conduct pre-clinical testing of Antroquinonol, which is showing promise as a way to prevent and combat Alzheimer’s disease. The results of preclinical efficacy testing will be used in the design of future clinical trials.